| A502 |
PDL241 Biosimilar（Anti-SLAMF7 / CS1 Reference Antibody）
Featured
|
|
|
| A503 |
Elotuzumab Biosimilar（Anti-SLAMF7 / CS1 Reference Antibody）
Featured
|
Elotuzumab is a monoclonal antibody directed against the SLAMF7 receptor. Elotuzumab has no significant antimyeloma activity when given as a single agent with relapsed or refractory multiple myeloma (RRMM). Elotuzumab results in improved response and outcome when combined with other antimyeloma agents. |
|
| A504 |
Idactamab Biosimilar（Anti-SLC1A5 / ASCT2 Reference Antibody）
Featured
|
Idactamab (INT-001) is an IgG1-κ antibody with in vivo activity across a spectrum of hematological malignancies. Idactamab can be used for prepare MEDI7247, a potent and specific ADC, targeting ASCT2 (SLC1A5). |
|
| A505 |
VB1-050 Biosimilar（Anti-SLC2A8 Reference Antibody）
Featured
|
|
|
| A506 |
LY2928057 Biosimilar（Anti-SLC40A1 Reference Antibody）
Featured
|
|
|
| A507 |
Amgen patent anti-Ferroportin Biosimilar(Anti-SLC40A1 Reference Antibody)
Featured
|
|
|
| A508 |
ASG-5ME Biosimilar(Anti-SLC44A4 Reference Antibody)
Featured
|
|
|
| A509 |
Agilvax Patent Anti-Slc7A11 Biosimilar(Anti-SLC7A11 Reference Antibody)
Featured
|
|
|
| A510 |
Sirtratumab Biosimilar(Anti-SLITRK6 Reference Antibody)
Featured
|
Sirtratumab is a human Igγ2 monoclonal antibody against SLIT and NTRK-like family 6 (Slitrk6). Sirtratumab can be used in research of cancer. |
|
| A511 |
Latozinemab Biosimilar(Anti-Sortilin / SORT1 Reference Antibody)
Featured
|
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research. |
|
| A512 |
Blosozumab Biosimilar(Anti-SOST / Sclerostin Reference Antibody)
Featured
|
Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis. |
|
| A513 |
Setrusumab Biosimilar（Anti-SOST / Sclerostin Reference Antibody）
Featured
|
Setrusumab (BPS 804) is a fully human monoclonal antibody targets sclerostin. Setrusumab efftively improves bone strength. Setrusumab can be used for the resesrch of Osteogenesis Imperfecta (OI) and cancer. |
|
| A514 |
Romosozumab Biosimilar（Anti-SOST / Sclerostin Reference Antibody）
Featured
|
Romosozumab is a humanized monoclonal anti-sclerostin antibody, it promotes bone formation and inhibits bone resorption by inhibiting sclerostin. Romosozumab can be used for the research of osteoporosis. |
|
| A515 |
Sonepcizumab Biosimilar（Anti-Sphingosine-1-phosphate Reference Antibody）
Featured
|
Sonepcizumab (LT 1009) is a fully human anti-S1P monoclonal antibody. Sonepcizumab has the potential for the research of metastatic renal cell carcinoma (mRCC). |
|
| A516 |
Expression DD patent anti-SIP Biosimilar（Anti-Sphingosine-1-phosphate Reference Antibody）
Featured
|
|
|
| A517 |
Bexmarilimab Biosimilar（Anti-STAB1 Reference Antibody）
Featured
|
Bexmarilimab (FP-1305) is a potent humanized anti-CLEVER-1 IgG4-antibody with an IC50 value of 4.51 nM. Bexmarilimab is capable of inducing a phenotypic M2 to M1 immune switch of tumor-associated macrophages. Bexmarilimab can be used in research of cancer. |
|
| A518 |
vandortuzumAb Biosimilar（Anti-STEAP1 Reference Antibody）
Featured
|
|
|
| A519 |
Genentech patent anti-STOP-1 Biosimilar（Anti-STOP1 Reference Antibody）
Featured
|
|
|
| A520 |
Indatuximab Biosimilar（Anti-Syndecan-1 / CD138 Reference Antibody）
Featured
|
|
|
| A521 |
Genentech patent anti-TAT226 Biosimilar（Anti-TAT226 Reference Antibody）
Featured
|
|
|
| A522 |
Zagotenemab Biosimilar（Anti-Tau Reference Antibody）
Featured
|
Zagotenemab (LY3303560) is a humanised anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research. |
|
| A523 |
Tilavonemab Biosimilar（Anti-Tau Reference Antibody）
Featured
|
Tilavonemab (ABBV-8E12) is a humanized anti-tau antibody that targets the extracellular form of pathological tau protein aggregates by binding to the N-terminal 25-30 amino acid residues of tau protein. Tilavonemab blocks the ability of human and mouse neurons to take up tau aggregates, reduces the loss of brain volume, slows the progression of tau pathology, and improves cognitive abilities in transgenic mice expressing mutant human tau. Tilavonemab is used in Alzheimer's disease research. |
|
| A524 |
Semorinemab Biosimilar（Anti-Tau Reference Antibody）
Featured
|
Semorinemab (RG 6100) is an anti-Tau humanized IgG4 monoclonal antibody, targets the N-terminal portion of the Tau protein (amino acid residues 6-23). Semorinemab binds with human Tau with a Kd value of 3.8 nM. Semorinemab can be used for the research of Alzheimer's Disease. |
|
| A525 |
Bepranemab Biosimilar（Anti-Tau Reference Antibody ）
Featured
|
Bepranemab (UCB 0107) is a humanized, full-length IgG4 monoclonal antibody that binds to a central tau epitope (amino acids 235-250). Bepranemab can be used for Alzheimer’s disease (AD) research. |
|
| A526 |
Gosuranemab Biosimilar（Anti-Tau Reference Antibody）
Featured
|
Gosuranemab (BMS-986168) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab binds to human N-terminal tau residues 15-22. Gosuranemab has the potential for the research of alzheimer’s disease (AD). |
|
| A527 |
LY3022859 Biosimilar（Anti-TBFbR2 Reference Antibody）
Featured
|
|
|
| A528 |
TOL101 Biosimilar（Anti-TCR Reference Antibody）
Featured
|
|
|
| A529 |
NKTT320 Biosimilar（Anti-TCR Reference Antibody）
Featured
|
|
|
| A530 |
Ontuxizumab Biosimilar（Anti-TEM1 / Endosialin / CD248 Reference Antibody）
Featured
|
Ontuxizumab (MORAb-004) is a humanized IgG1/κ anti-endosialin (TEM-1 or CD248) monoclonal antibody with antitumor effects. Ontuxizumab can be used for the research of cancer. |
|
| A531 |
Fox Chase patent anti-TEM7R Biosimilar（Anti-TEM7R / PLXDC2 Reference Antibody）
Featured
|
|
|
